BOOST Pharma Secures €3.1 Million to Advance Stem Cell Therapy for Osteogenesis Imperfecta
核心洞察
Stockholm-based BOOST Pharma (搜索) raised €3.1 million from Sound Bioventures (搜索) to advance BT-101, a mesenchymal stem cell therapy for osteogenesis imperfecta (搜索) in children.
BT-101 demonstrated promising results in four children with Type III and IV osteogenesis imperfecta (搜索), showing reduced fractures and improved growth compared to contemporary patients.
The therapy is designed for early intervention in infants to address the underlying cause of brittle bone disease (搜索) and represents a potential first disease-modifying treatment for this condition.
Stockholm-based BOOST Pharma (搜索) announced that Sound Bioventures (搜索) has joined its investor syndicate with a €3.1 million investment to support continued clinical development of BT-101, the company's pioneering stem cell-based therapy for osteogenesis imperfecta (搜索) (OI), also known as brittle bone disease (搜索). The financing positions BOOST Pharma to advance what could become the first disease-modifying therapy for this devastating genetic condition that currently has no approved treatments.
Novel Mesenchymal Stem Cell Approach
BT-101 represents a novel mesenchymal stem cell therapy specifically designed for children born with OI. The treatment is intended for early intervention, administered to infants to address the underlying cause of OI and reduce fracture frequency in affected children. According to the company, once injected, the cells migrate to the bone of patients with OI, where they engraft and initiate bone formation.
"We are honored to welcome Sound Bioventures (搜索) to our syndicate—a collaborative, hands-on investor group that shares our vision of transforming care for children living with rare skeletal diseases," said Ingelise Saunders, Chair of BOOST Pharma (搜索). "Their commitment strengthens BOOST Pharma's position as a leader in cell therapy for genetic bone disorders and enables continued progress of BT-101 towards the clinic."
Promising Clinical Evidence
BOOST Pharma (搜索) has obtained human proof-of-concept for BT-101 after treating four children with Type III and IV OI, with follow-up extending through adolescence. The treated children demonstrated several encouraging outcomes: they followed their own growth curve, showed increased lengthwise growth compared to contemporary OI patients, and experienced a significant reduction in bone fractures. The cells were considered safe with no adverse reactions and no immune responses toward the donor mesenchymal stem cells (搜索).
In preclinical mouse models, BT-101 demonstrated higher calcium deposition, higher alkaline phosphatase activity, and significant ectopic bone formation, supporting the therapy's potential mechanism of action.
Early Intervention Strategy
BT-101 therapy is designed to begin at the prenatal stage when OI is first diagnosed, or as early as possible after birth. This early intervention approach aims to address the disease at its earliest possible stage, potentially maximizing treatment benefits for patients in later years, including stronger bones and possibly improved lung function.
Research Foundation and Development
Founded in 2019, BOOST Pharma (搜索) is based on years of collaborative research from Karolinska Institute (搜索) in Stockholm, focusing on novel cell therapy treatments for osteogenesis imperfecta (搜索). The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have reportedly demonstrated that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.
Investment Significance
"We believe BOOST Pharma (搜索)'s innovative approach to treating osteogenesis imperfecta (搜索) has enormous potential to deliver not only clinical impact for patients but also durable value creation. We look forward to working together to reach new milestones," said Johan Kördel, Managing Partner at Sound Bioventures (搜索).
This investment reflects a broader pattern of European funding for advanced cell and gene therapy ventures in 2025, with Sweden showing a growing concentration of regenerative medicine innovation. The funding will enable BOOST Pharma (搜索) to accelerate clinical development and move closer to delivering the first disease-modifying therapy for OI.